Volcano Therapeutics Names Scott Huennekens As President & CEO
LAGUNA NIGUEL, Calif., July 1 /PRNewswire/ -- Volcano Therapeutics, Inc. an early stage medical device company today announced it has hired medical industry executive Scott Huennekens as President and CEO. Mr. Huennekens brings over 10 years of experience in cardiovascular disease and minimally invasive medical devices to Volcano. Volcano Therapeutics is focused on the discovery, development and commercialization of products for the detection and treatment of vulnerable plaques located in the coronary or peripheral arteries. Olav Bergheim, Volcano Chairman of the Board, commented, "Scott combines strong leadership and communication skills with a solid track record in the medical device industry. On behalf of all the board members, we are very pleased to have found someone with Scott's breadth of experience in cardiovascular disease as well as start-up to multi-national companies." Mr. Huennekens added, "In the U.S., each year over 500,000 people die from heart attacks caused primarily from vulnerable plaques, approximately a person every minute. Volcano has a vision of significantly reducing the number of heart attacks through technological developments and strong relationships with our clinical partners. Given Volcano's single minded focus on vulnerable plaques and broad base of diagnostic and therapeutic technologies in development, we are well-positioned to be first in developing solutions that will meet significant unmet clinical needs and help thousands of people." Prior to joining Volcano, Mr. Huennekens was the President and CEO of Digirad Corp, the leader in solid-state nuclear cardiology imaging. At Digirad, he was responsible for raising over $60M of venture capital and moving the company from the product development phase to product commercialization. As CEO, he led the company's growth from 45 to 300+ employees and revenue from $7M to $32M in 2001. Prior to Digirad, he was at Baxter Healthcare in their Cardiovascular Group where he held various sales, marketing, and general management positions. Huennekens holds a Bachelor of Science in Business Administration from University of Southern California and a Masters in Business Administration from Harvard Graduate School of Business. About Volcano Therapeutics Volcano Therapeutics, Inc., a privately held early stage medical device with headquarters in Laguna Hills, CA, was founded in 2001. Volcano is focused on the discovery, development and commercialization of products for the detection and treatment of vulnerable plaque in the coronary arteries and peripheral vascular system. Currently under development are technologies that could be potentially useful in detecting and treating patients who are at risk for developing plaque rupture and subsequent adverse cardiac events. For more information, please visit us at www.volcanotherapeutics.com . MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X33419146
SOURCE Volcano Therapeutics, Inc.
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.